RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance

Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises in these patients and is a major clinical problem. The BRCA1(185delAG) allele is a common inherited...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Invest
Prif Awduron: Wang, Yifan, Krais, John J., Bernhardy, Andrea J., Nicolas, Emmanuelle, Cai, Kathy Q., Harrell, Maria I., Kim, Hyoung H., George, Erin, Swisher, Elizabeth M., Simpkins, Fiona, Johnson, Neil
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Clinical Investigation 2016
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4966309/
https://ncbi.nlm.nih.gov/pubmed/27454289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI87033
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg